Clinical trial · Interventional
Optimized Magnetic Resonance Brachytherapy (MR BT) in Cervix Cancer
Implementation of Optimized Magnetic Resonance Image-guided Intra-uterine Brachytherapy in Cervical Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with cervix cancer usually require external radiation given to the whole pelvis then an internal radiation boost, also called brachytherapy, to treat any remaining tumour. Standard brachytherapy has been used successfully for many years, but does not take into account differences in the shape of the tumour or normal structures between patients. This study aims to implement individualized -optimized- brachytherapy, based on international recommendations. MR scanning with the intra-uterine applicator in place allows improved identification of residual tumour and normal structures, allowing brachytherapy to be individualized for each patient with the aim to reduce side-effects and improve outcome. Additionally, repeating MR scans during brachytherapy treatment will allow further assessment on motion of the applicator during treatment and the effect on radiation dose. Sexual health assessments aim to identify the relationship between sexual health and treatment effects.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervix Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| optimised magnetic resonance image-guided intra-uterine brachytherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- (MR BT) in Cervix Cancer
- interventionNames
- Radiation: optimised magnetic resonance image-guided intra-uterine brachytherapy
Primary outcomes (1)
- measure
- Feasibility of clinical implementation of an effective and safe protocol for optimised MR image guided intra-uterine brachytherapy for cervix cancer.
- timeFrame
- 36 months
Secondary outcomes (1)
- measure
- Determine local control,overall survival,acute & late toxicity, & sexual health of patients treated with optimised intra-uterine BT. Evaluate stability of the intra-uterine applicator during BT. Evaluate dose homogeneity of BT for cervix cancer.
- timeFrame
- 36 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age over 18 years * ECOG performance status 0-2 * Histological confirmed carcinoma cervix * Decision to treat with EBRT (+/- concurrent chemotherapy), and PDR BT * Ability to comply with study protocol * Patient informed consent Exclusion Criteria: * Unable to or unwilling to give informed consent * Not suitable for intra-uterine brachytherapy * Previous treatment for pelvic malignancy * Previous pelvic radiotherapy * Serious claustrophobia * Previous history of metallic injury to the eye * Non-removable implants contraindicated for MRI * Cardiac pacemaker * Other contraindication to MRI -Pregnancy, lactation or child-bearing potential without adequate contraception -
References
Publications (0)
Data not yet available